$44.69
00.00%
Last update: 4:00 PM
15 minutes delayed
Agios Pharmaceuticals
AGIONASDAQ
Agios Pharmaceuticals (NASDAQ:AGIO) Stock, Analyst Ratings, Price Targets, Predictions
Agios Pharmaceuticals Inc has a consensus price target of $42.36, established from looking at the 31 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, Goldman Sachs, and RBC Capital on June 13, 2024, June 4, 2024, and June 4, 2024. With an average price target of $50.67 between JP Morgan, Goldman Sachs, and RBC Capital, there's an implied 15.76% upside for Agios Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
JP Morgan
Goldman Sachs
RBC Capital
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Agios Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/17/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt | — | Reiterates | → Overweight | Get Alert |
| 06/13/2024 | Buy Now | 5.09% | JP Morgan | Tessa Romero | → $46 | Reinstates | Neutral → Neutral | Get Alert |
| 06/04/2024 | Buy Now | 21.09% | Goldman Sachs | Salveen Richter | $33 → $53 | Maintains | Neutral | Get Alert |
| 06/04/2024 | Buy Now | 21.09% | RBC Capital | Gregory Renza | $44 → $53 | Maintains | Outperform | Get Alert |
| 05/03/2024 | Buy Now | -24.61% | Goldman Sachs | Salveen Richter | $29 → $33 | Maintains | Neutral | Get Alert |
| 04/09/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt | — | Reiterates | → Overweight | Get Alert |
| 02/23/2024 | Buy Now | -31.46% | JP Morgan | Tessa Romero | $31 → $30 | Maintains | Neutral | Get Alert |
| 02/16/2024 | Buy Now | -4.04% | RBC Capital | Gregory Renza | $43 → $42 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | -36.03% | Goldman Sachs | Salveen Richter | $32 → $28 | Maintains | Neutral | Get Alert |
| 08/07/2023 | Buy Now | -26.89% | JP Morgan | Tessa Romero | $33 → $32 | Maintains | Neutral | Get Alert |
| 06/27/2023 | Buy Now | -4.04% | RBC Capital | Kennen MacKay | $40 → $42 | Maintains | Outperform | Get Alert |
| 02/03/2023 | Buy Now | -6.33% | Piper Sandler | Christopher Raymond | → $41 | Initiates | → Overweight | Get Alert |
| 12/01/2022 | Buy Now | -24.61% | JP Morgan | Tessa Romero | $48 → $33 | Maintains | Neutral | Get Alert |
| 11/17/2022 | Buy Now | -26.89% | Goldman Sachs | Salveen Richter | $17 → $32 | Upgrade | Sell → Neutral | Get Alert |
| 08/05/2022 | Buy Now | -15.47% | SVB Leerink | Andrew Berens | $33 → $37 | Maintains | Outperform | Get Alert |
| 07/27/2022 | Buy Now | -24.61% | SVB Leerink | Andrew Berens | → $33 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/24/2022 | Buy Now | -63.45% | Goldman Sachs | Salveen Richter | $20 → $16 | Maintains | Sell | Get Alert |
| 05/17/2022 | Buy Now | -24.61% | SVB Leerink | Andrew Berens | $30 → $33 | Maintains | Market Perform | Get Alert |
| 03/07/2022 | Buy Now | -47.45% | Goldman Sachs | Salveen Richter | $37 → $23 | Maintains | Sell | Get Alert |
| 03/03/2022 | Buy Now | 119.33% | HC Wainwright & Co. | Michael King | $98 → $96 | Maintains | Buy | Get Alert |
| 02/25/2022 | Buy Now | 53.07% | RBC Capital | Kennen MacKay | $61 → $67 | Maintains | Outperform | Get Alert |
| 02/24/2022 | Buy Now | 119.33% | HC Wainwright & Co. | Michael King | $98 → $96 | Maintains | Buy | Get Alert |
| 02/22/2022 | Buy Now | -31.46% | SVB Leerink | Andrew Berens | $32 → $30 | Maintains | Market Perform | Get Alert |
| 02/18/2022 | Buy Now | 123.9% | HC Wainwright & Co. | Michael King | $95 → $98 | Maintains | Buy | Get Alert |
| 02/16/2022 | Buy Now | 0.53% | Canaccord Genuity | John Newman | $52 → $44 | Maintains | Buy | Get Alert |
| 12/03/2021 | Buy Now | 23.37% | B of A Securities | Greg Harrison | — | Initiates | → Buy | Get Alert |
| 11/18/2021 | Buy Now | -4.04% | SVB Leerink | Andrew Berens | — | Maintains | Market Perform | Get Alert |
| 11/04/2021 | Buy Now | 117.04% | HC Wainwright & Co. | Michael King | — | Maintains | Buy | Get Alert |
| 07/30/2021 | Buy Now | 112.47% | HC Wainwright & Co. | Michael King | — | Maintains | Buy | Get Alert |
| 07/30/2021 | Buy Now | -10.9% | Goldman Sachs | Salveen Richter | — | Downgrade | Neutral → Sell | Get Alert |
| 07/01/2021 | Buy Now | — | Raymond James | Danielle Brill | — | Initiates | → Market Perform | Get Alert |
FAQ
What is the target price for Agios Pharmaceuticals (AGIO) stock?
The latest price target for Agios Pharmaceuticals (NASDAQ:AGIO) was reported by Cantor Fitzgerald on June 17, 2024. The analyst firm set a price target for $0.00 expecting AGIO to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Agios Pharmaceuticals (AGIO)?
The latest analyst rating for Agios Pharmaceuticals (NASDAQ:AGIO) was provided by Cantor Fitzgerald, and Agios Pharmaceuticals reiterated their overweight rating.
When was the last upgrade for Agios Pharmaceuticals (AGIO)?
The last upgrade for Agios Pharmaceuticals Inc happened on November 17, 2022 when Goldman Sachs raised their price target to $32. Goldman Sachs previously had a sell for Agios Pharmaceuticals Inc.
When was the last downgrade for Agios Pharmaceuticals (AGIO)?
The last downgrade for Agios Pharmaceuticals Inc happened on July 30, 2021 when Goldman Sachs changed their price target from $58 to $39 for Agios Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Agios Pharmaceuticals (AGIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agios Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agios Pharmaceuticals was filed on June 17, 2024 so you should expect the next rating to be made available sometime around June 17, 2025.
Is the Analyst Rating Agios Pharmaceuticals (AGIO) correct?
While ratings are subjective and will change, the latest Agios Pharmaceuticals (AGIO) rating was a reiterated with a price target of $0.00 to $0.00. The current price Agios Pharmaceuticals (AGIO) is trading at is $44.69, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.